242 related articles for article (PubMed ID: 7593709)
1. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition.
Schadel M; Wu D; Otton SV; Kalow W; Sellers EM
J Clin Psychopharmacol; 1995 Aug; 15(4):263-9. PubMed ID: 7593709
[TBL] [Abstract][Full Text] [Related]
2. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.
Capon DA; Bochner F; Kerry N; Mikus G; Danz C; Somogyi AA
Clin Pharmacol Ther; 1996 Sep; 60(3):295-307. PubMed ID: 8841152
[TBL] [Abstract][Full Text] [Related]
3. Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A.
von Moltke LL; Greenblatt DJ; Grassi JM; Granda BW; Venkatakrishnan K; Schmider J; Harmatz JS; Shader RI
J Pharm Pharmacol; 1998 Sep; 50(9):997-1004. PubMed ID: 9811160
[TBL] [Abstract][Full Text] [Related]
4. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
[TBL] [Abstract][Full Text] [Related]
5. Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.
Yubero-Lahoz S; Pardo R; Farré M; O'Mahony B; Torrens M; Mustata C; Pérez-Mañá C; Carbó ML; de la Torre R
Clin Pharmacokinet; 2011 May; 50(5):319-29. PubMed ID: 21456632
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1.
Schmider J; Greenblatt DJ; Fogelman SM; von Moltke LL; Shader RI
Biopharm Drug Dispos; 1997 Apr; 18(3):227-40. PubMed ID: 9113345
[TBL] [Abstract][Full Text] [Related]
7. CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans.
Jacqz-Aigrain E; Funck-Brentano C; Cresteil T
Pharmacogenetics; 1993 Aug; 3(4):197-204. PubMed ID: 8220439
[TBL] [Abstract][Full Text] [Related]
8. The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes.
Kerry NL; Somogyi AA; Bochner F; Mikus G
Br J Clin Pharmacol; 1994 Sep; 38(3):243-8. PubMed ID: 7826826
[TBL] [Abstract][Full Text] [Related]
9. Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites.
Ching MS; Blake CL; Ghabrial H; Ellis SW; Lennard MS; Tucker GT; Smallwood RA
Biochem Pharmacol; 1995 Sep; 50(6):833-7. PubMed ID: 7575645
[TBL] [Abstract][Full Text] [Related]
10. Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6.
Zhang Y; Britto MR; Valderhaug KL; Wedlund PJ; Smith RA
Clin Pharmacol Ther; 1992 Jun; 51(6):647-55. PubMed ID: 1611804
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and polymorphic oxidation of dextromethorphan in a Japanese population.
Nagai N; Kawakubo T; Kaneko F; Ishii M; Shinohara R; Saito Y; Shimamura H; Ohnishi A; Ogata H
Biopharm Drug Dispos; 1996 Jul; 17(5):421-33. PubMed ID: 8830977
[TBL] [Abstract][Full Text] [Related]
12. Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan.
McCune JS; Lindley C; Decker JL; Williamson KM; Meadowcroft AM; Graff D; Sawyer WT; Blough DK; Pieper JA
J Clin Pharmacol; 2001 Jul; 41(7):723-31. PubMed ID: 11452704
[TBL] [Abstract][Full Text] [Related]
13. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation.
Jones DR; Gorski JC; Haehner BD; O'Mara EM; Hall SD
Clin Pharmacol Ther; 1996 Oct; 60(4):374-84. PubMed ID: 8873685
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups.
Britzi M; Bialer M; Arcavi L; Shachbari A; Kapitulnik T; Soback S
Ther Drug Monit; 2000 Oct; 22(5):510-6. PubMed ID: 11034254
[TBL] [Abstract][Full Text] [Related]
15. Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis.
Hou ZY; Chen CP; Yang WC; Lai MD; Buchert ET; Chung HM; Pickle LW; Woosley RL
Clin Pharmacol Ther; 1996 Apr; 59(4):411-7. PubMed ID: 8612385
[TBL] [Abstract][Full Text] [Related]
16. Investigation of terbinafine as a CYP2D6 inhibitor in vivo.
Abdel-Rahman SM; Gotschall RR; Kauffman RE; Leeder JS; Kearns GL
Clin Pharmacol Ther; 1999 May; 65(5):465-72. PubMed ID: 10340911
[TBL] [Abstract][Full Text] [Related]
17. A validated SIM GC/MS method for the simultaneous determination of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in biological matrices and its application to in vitro CYP2D6 and CYP3A4 inhibition study.
Spanakis M; Vizirianakis IS; Mironidou-Tzouveleki M; Niopas I
Biomed Chromatogr; 2009 Nov; 23(11):1131-7. PubMed ID: 19444798
[TBL] [Abstract][Full Text] [Related]
18. Contribution of cytochrome P-4502D6 phenotype to the neuromodulatory effects of dextromethorphan.
Desmeules JA; Oestreicher MK; Piguet V; Allaz AF; Dayer P
J Pharmacol Exp Ther; 1999 Feb; 288(2):607-12. PubMed ID: 9918565
[TBL] [Abstract][Full Text] [Related]
19. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.
Tamminga WJ; Wemer J; Oosterhuis B; Weiling J; Wilffert B; de Leij LF; de Zeeuw RA; Jonkman JH
Eur J Clin Pharmacol; 1999 May; 55(3):177-84. PubMed ID: 10379632
[TBL] [Abstract][Full Text] [Related]
20. The antitussive effect of dextromethorphan in relation to CYP2D6 activity.
Abdul Manap R; Wright CE; Gregory A; Rostami-Hodjegan A; Meller ST; Kelm GR; Lennard MS; Tucker GT; Morice AH
Br J Clin Pharmacol; 1999 Sep; 48(3):382-7. PubMed ID: 10510150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
